Q32 Bio Inc. (QTTB)
NASDAQ: QTTB · Real-Time Price · USD
15.15
-0.23 (-1.50%)
Jul 24, 2026, 4:00 PM EDT - Market closed
Q32 Bio Revenue
In the year 2025, Q32 Bio had annual revenue of $53.74M.
Revenue (ttm)
$53.74M
Revenue Growth
n/a
P/S Ratio
4.78
Revenue / Employee
$2,442,591
Employees
22
Market Cap
256.89M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 53.74M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | -6.65M | -9.86M | - |
| Dec 31, 2022 | 3.21M | -30.76M | -90.56% |
| Dec 31, 2021 | 33.97M | 31.27M | 1,157.25% |
| Dec 31, 2020 | 2.70M | 1.04M | 62.18% |
| Dec 31, 2019 | 1.67M | -3.66M | -68.70% |
| Dec 31, 2018 | 5.32M | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Niagen Bioscience | 130.42M |
| Agenus | 123.87M |
| Fulcrum Therapeutics | 80.00M |
| Bicycle Therapeutics | 63.50M |
| Sol-Gel Technologies | 18.47M |
| Lineage Cell Therapeutics | 14.78M |
| Opus Genetics | 11.98M |
| Outlook Therapeutics | 333.14K |
QTTB News
- 8 days ago - Q32 Bio files to sell 6.88M shares of common stock for holders - TheFly
- 8 days ago - Q32 Bio Registration statement: Registration filing - Filings
- 11 days ago - Q32 Bio 6.03M share secondary priced at $18.25 - TheFly
- 11 days ago - Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants - PRNewsWire
- 12 days ago - Q32 Bio announces $200M common stock offering - TheFly
- 12 days ago - Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - PRNewsWire
- 12 days ago - Q32 Bio price target raised to $36 from $14 at Mizuho - TheFly
- 12 days ago - Why Q32 Bio investors should take profits in the stock after 81% rally - Invezz